Neurocrine Biosciences, Inc. announced that its Board of Directors has authorized a new share repurchase program, allowing the company to repurchase up to $500 million of its shares. This authorization is subject to market conditions and reflects the company's capital allocation strategy.
This new share repurchase program is in addition to a previously announced $300 million accelerated repurchase program that was completed in early February 2025. The company's approach balances driving sustained revenue growth through investments in commercial products like INGREZZA and CRENESSITY, advancing its R&D pipeline, and returning capital to shareholders.
Repurchases may be executed through various methods, including open-market transactions, privately negotiated transactions, and accelerated share repurchases, in accordance with applicable securities laws. This move signals confidence in the company's underlying value and financial strength.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.